Filing Flows

Filing Flows › Keros Therapeutics (KROS) › Next earnings date

Keros Therapeutics (KROS) earnings: beat the estimate

Keros Therapeutics (KROS) reported on Nov 5, 2026 and beat the EPS estimate: $0.70 against −$0.86 (+181.4%). Revenue was $40.0M for Q3 2026, +183% year over year. It beat the EPS estimate in 40% of the quarters on record.

Last result+181.4% vs estimate
Beat rate40%

The last report

Keros Therapeutics reported revenue of $40.0M for the third quarter 2026 (+183% Y/Y), net earnings $14.2M. How it makes money → · Every quarter →

Keros Therapeutics: EPS against the estimate, last 5 reportsKeros Therapeutics: EPS against the estimate, last 5 reportsEstimateReported−$0.92−$0.18Nov 25−$0.45−$0.86Mar 26−$0.92−$1.21May 26−$1.24−$1.45Aug 26−$0.86$0.70Nov 26
Latest (Nov 26): Estimate −$0.86, Reported $0.70.

Keros Therapeutics' latest quarter

Keros Therapeutics, Q3 2026: revenue $40.0M (+183% year over year), operating margin 32.0%, net earnings $14.2M, operating cash flow $3.4M. The chart follows the revenue to costs, profit and cash.

Questions

Did Keros Therapeutics beat earnings?

Keros Therapeutics (KROS) reported on Nov 5, 2026 and beat the EPS estimate: $0.70 against −$0.86 (+181.4%).

When does KROS report earnings?

The next date is not set yet.

Does Keros Therapeutics usually beat earnings?

It beat the consensus EPS estimate in 40% of the quarters on record.

Open the interactive view →

Updated Nov 8, 2026. Read automatically from SEC filings and public data; errors are possible. Not investment advice.